文献速递类风湿关节炎其他结缔组织病

系统性自身免疫性风湿病患者COVID-19门诊治疗与未治疗结局比较:回顾性队列研究

Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2023-01-23

该回顾性队列研究纳入704例系统性自身免疫性风湿病合并COVID-19患者,比较门诊SARS-CoV-2治疗与否的结局。426例(61%)接受门诊治疗,其中9例(2.1%)发生住院或死亡,未治疗组278例中49例(17.6%)发生住院或死亡,校正后OR为0.12(95%CI 0.05-0.25)。318例接受口服门诊治疗的患者中25例(7.9%)记录到COVID-19反弹。

要点

  • 门诊SARS-CoV-2治疗与较低的严重COVID-19结局几率相关(校正OR 0.12,95%CI 0.05-0.25)。
  • 426例接受门诊治疗者中9例(2.1%)住院或死亡,278例未治疗者中49例(17.6%)。
  • 318例接受口服门诊治疗者中25例(7.9%)记录到COVID-19反弹。

核心结论

  • 与未接受门诊治疗相比,门诊治疗与较低的严重COVID-19结局几率相关。
  • 这些发现强调了系统性自身免疫性风湿病合并COVID-19患者接受门诊SARS-CoV-2治疗的重要性,以及进一步研究COVID-19反弹的必要性。

研究设计与样本

  • 在美国马萨诸塞州波士顿Mass General Brigham Integrated Health Care System进行的回顾性队列研究。
  • 纳入2022年1月23日至5月30日期间COVID-19发病、年龄18岁及以上、既往存在系统性自身免疫性风湿病的患者。
  • 通过阳性PCR或抗原检测(索引日期定义为首次阳性检测日期)识别COVID-19,通过诊断代码和免疫调节剂处方识别系统性自身免疫性风湿病。
  • 门诊SARS-CoV-2治疗通过病历审查确认。
  • 采用多变量逻辑回归评估门诊SARS-CoV-2治疗与未治疗同严重COVID-19结局的关联,校正年龄、性别、种族、合并症和肾功能。

主要发现

  • 2022年1月23日至5月30日期间共识别并纳入704例患者(平均年龄58.4岁[SD 15.9];536例[76%]为女性,168例[24%]为男性;590例[84%]为白人,39例[6%]为黑人;347例[49%]患有类风湿关节炎)。
  • 门诊SARS-CoV-2治疗频率随日历时间增加(p<0.0001)。
  • 704例患者中426例(61%)接受了门诊治疗(307例[44%]使用奈玛特韦-利托那韦,105例[15%]使用单克隆抗体,5例[1%]使用莫诺拉韦,3例[<1%]使用瑞德西韦,6例[1%]使用联合治疗)。
  • 426例接受门诊治疗的患者中9例(2.1%)发生住院或死亡,而未接受门诊治疗的278例中49例(17.6%)发生住院或死亡(校正年龄、性别、种族、合并症和肾功能后的比值比[OR] 0.12,95%CI 0.05-0.25)。
  • 318例接受口服门诊治疗的患者中25例(7.9%)记录到COVID-19反弹。

关键数值与推荐

  • 主要结局严重COVID-19定义为索引日期后30天内住院或死亡。
  • COVID-19反弹定义为治疗后记录到SARS-CoV-2检测阴性后再次出现阳性检测。
  • 门诊治疗与未治疗同严重COVID-19的校正OR为0.12(95%CI 0.05-0.25)。
  • 门诊SARS-CoV-2治疗频率随日历时间增加(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some patients with systemic autoimmune rheumatic disease and immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS-CoV-2 treatments on COVID-19 outcomes among patients with systemic autoimmune rheumatic disease is unclear. We aimed to evaluate temporal trends, severe outcomes, and COVID-19 rebound among patients with systemic autoimmune rheumatic disease and COVID-19 who received outpatient SARS-CoV-2 treatment compared with those who did not receive outpatient treatment. METHODS: We did a retrospective cohort study at Mass General Brigham Integrated Health Care System, Boston, MA, USA. We included patients aged 18 years or older with a pre-existing systemic autoimmune rheumatic disease, who had COVID-19 onset between Jan 23 and May 30, 2022. We identified COVID-19 by positive PCR or antigen test (index date defined as the date of first positive test) and systemic autoimmune rheumatic diseases using diagnosis codes and immunomodulator prescription. Outpatient SARS-CoV-2 treatments were confirmed by medical record review. The primary outcome was severe COVID-19, defined as hospitalisation or death within 30 days after the index date. COVID-19 rebound was defined as documentation of a negative SARS-CoV-2 test after treatment followed by a newly positive test. The association of outpatient SARS-CoV-2 treatment versus no outpatient treatment with severe COVID-19 outcomes was assessed using multivariable logistic regression. FINDINGS: Between Jan 23 and May 30, 2022, 704 patients were identified and included in our analysis (mean age 58·4 years [SD 15·9]; 536 [76%] were female and 168 [24%] were male, 590 [84%] were White and 39 [6%] were Black, and 347 [49%] had rheumatoid arthritis). Outpatient SARS-CoV-2 treatments increased in frequency over calendar time (p<0·0001). A total of 426 (61%) of 704 patients received outpatient treatment (307 [44%] with nirmatrelvir-ritonavir, 105 [15%] with monoclonal antibodies, five [1%] with molnupiravir, three [<1%] with remdesivir, and six [1%] with combination treatment). There were nine (2·1%) hospitalisations or deaths among 426 patients who received outpatient treatment compared with 49 (17·6%) among 278 who did not receive outpatient treatment (odds ratio [adjusted for age, sex, race, comorbidities, and kidney function] 0·12, 95% CI 0·05-0·25). 25 (7·9%) of 318 patients who received oral outpatient treatment had documented COVID-19 rebound. INTERPRETATION: Outpatient treatment was associated with lower odds of severe COVID-19 outcomes compared with no outpatient treatment. These findings highlight the importance of outpatient SARS-CoV-2 treatment for patients with systemic autoimmune rheumatic disease and COVID-19 and the need for further research on COVID-19 rebound. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Qian G, Wang X, Patel NJ, et al. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study. Lancet Rheumatol. 2023. PMID: 36844970. doi:10.1016/S2665-9913(23)00006-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。